Pharmacoepidemiology and drug safety
-
Pharmacoepidemiol Drug Saf · Jun 2020
Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy.
Emerging evidence suggests metformin compared with sulfonylurea is associated with an 8% to 10% lower risk for dementia. Guidelines recommend metformin as initial diabetes treatment, but there is still the question of treatment timing. Thus, the risk of dementia associated with initiating metformin compared with not initiating or delaying treatment was examined. ⋯ Results do not support initiating metformin earlier to prevent cognitive decline and, thus, may dampen enthusiasm for metformin as a potential antidementia drug. Randomized clinical trials could help clarify the relationship between metformin and cognitive decline.